- Conditions
- Depressive Disorder, Major
- Interventions
- JNJ-89495120, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2329–2352
of 10,572
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Episodic Migraine
- Interventions
- Atogepant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 685 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 113
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
- Conditions
- Intra-amniotic Infection
- Interventions
- Not listed
- Lead sponsor
- ProteoGenix, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 21
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 16 more
- Conditions
- Mild Persistent Asthma
- Interventions
- methacholine chloride, placebo ProAir HFA, ProAir HFA, Lupin albuterol HFA MDI, placebo Lupin albuterol HFA MDI
- Other · Drug
- Lead sponsor
- Lupin, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 17
- States / cities
- Huntington Beach, California • Mission Viejo, California • Rolling Hills Estates, California + 14 more
- Conditions
- Hypertension
- Interventions
- irbesartan, placebo, PS433540
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 40
- States / cities
- Pell City, Alabama • Tempe, Arizona • Tucson, Arizona + 36 more
- Conditions
- Autism Spectrum Disorder, Autism
- Interventions
- EarliPoint Diagnosis, Clinically Certain Expert Clinician Diagnosis (CC-ECD)
- Device · Behavioral
- Lead sponsor
- EarliTec Diagnostics, Inc
- Industry
- Eligibility
- 31 Months to 84 Months
- Enrollment
- 929 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Altanta, Georgia • Iowa City, Iowa + 6 more
- Conditions
- Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Hypertension
- Interventions
- FETO, Fetal Endoluminal Tracheal Occlusion
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2033
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Breast Cancer
- Interventions
- filgrastim, cyclophosphamide, doxorubicin, paclitaxel, surgery
- Biological · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 314
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 204 more
- Conditions
- Benign Prostatic Hypertrophy
- Interventions
- Cetrorelix Pamoate
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 56
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Laguna Hills, California + 49 more
- Conditions
- Ethanol Intoxication
- Interventions
- ADX-629, Placebo
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 208
- States / cities
- Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more
- Conditions
- Chronic Heart Failure
- Interventions
- Vasopressin V2 Receptor Antagonist
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more
- Conditions
- Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
- Interventions
- Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 77
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more
- Conditions
- Pneumonia
- Interventions
- Amoxicillin, Amoxicillin-clavulanate, Cefdinir, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 71 Months
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Louisville, Kentucky + 6 more
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- LY3016859, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
- Conditions
- Arthritis, Rheumatoid, Crohn Disease, Psoriasis
- Interventions
- Infliximab (Remicade)
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,971 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- LY2523355, ixabepilone, pegfilgrastim, filgrastim
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 12
- States / cities
- Fort Myers, Florida • Pensacola, Florida • Gainesville, Georgia + 9 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Fresno, California • Torrance, California • Orlando, Florida + 8 more
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Interventions
- LY2127399, Placebo every 2 weeks, Placebo every 4 weeks
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 88
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 84 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
- Interventions
- RP1, nivolumab
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
- Conditions
- Schizophrenia
- Interventions
- Brexpiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 17
- States / cities
- Dothan, Alabama • Anaheim, California • Culver City, California + 14 more
- Conditions
- Neuroblastoma
- Interventions
- filgrastim, carboplatin, etoposide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, iobenguane I 131, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
- Conditions
- Advanced Cancer
- Interventions
- AGEN1777, a PD-1 inhibitor
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Grand Rapids, Michigan • Southfield, Michigan • Cincinnati, Ohio + 4 more
- Conditions
- Head and Neck Cancer
- Interventions
- carboplatin, docetaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more